Keywords: s-p, licenses, sankyo, cardio, drug, latin, territories

S-P licenses Sankyo's cardio drug in Latin territories

Article | 15 August 2005

Print This

US drug major Schering-Plough has entered into a license agreement with Japan's Sankyo for olmesartan for the treatment of hypertension.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in